1. Male and female patients 18 years of age and older.
2. Have histologically or cytologically confirmed lung cancer.
3. Documented next generation sequencing assay performed on tumor sample in Clinical Laboratory Improvement Amendments (CLIA)-approved laboratory.
4. Have at least 1 measurable lesion per RECIST v1.1
5. Have life expectancy ≥3 months.
6. Have Eastern Cooperative Oncology Group (ECOG) performance status ≤2.
7. Must provide a signed and dated informed consent indicating that the participants have been informed of all pertinent aspects of the study, including the potential risks, and is willingly participating.
8. Have the willingness and ability to comply with scheduled visits and study procedures.
9. Cohort A, confirmed EGFR mutation.
You may not be if
1. Implanted electronic devices (e.g. pacemaker) in the upper torso.
2. Have been diagnosed with another primary malignancy within the past 3 years (except for adequately treated non-melanoma skin cancer, cervical cancer in situ or prostate cancer, which are allowed within 3 years).
3. Have any condition or illness that, in the opinion of the investigator, would compromise participants' safety or interfere with the evaluation.
